ArticleInternational journal of general medicine2026
Diagnostic Utility of Extracellular Levels of Serum Amyloid P and Proteoglycan 4: A Case-Control Study in Gestational Diabetes Mellitus.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gestational diabetes mellitus (GDM) is linked to excessive inflammatory activation during pregnancy. Serum amyloid P component (SAP) and proteoglycan 4 (PRG4) participate in inflammatory and placental regulatory processes; however, their relationships with GDM remain insufficiently clarified. This exploratory single-center retrospective study aimed to preliminarily investigate the associations of circulating SAP and PRG4 concentrations with GDM. Methods: A total of 111 Pregnant women undergoing 24-28 week OGTT screening were enrolled and divided into the GDM group and normal glucose tolerance (NGT) group. Serum SAP and PRG4 levels were measured by ELISA. Baseline characteristics, biomarker concentrations and relevant clinical indices were compared between groups. Receiver operating characteristic (ROC) curve and logistic regression analyses were used to evaluate their associations and predictive value. Results: The median serum levels of proteoglycan 4 (PRG4) and serum amyloid P (SAP) were 1.81 (1.11, 2.60) ng/mL and 308.55 (227.06, 437.02) ng/mL, respectively. The serum SAP level in the GDM group [437.66 (366.69, 543.72) ng/mL] was significantly higher than that in the NGT group [232.22 (203.12, 295.86) ng/mL] ( Conclusion: Elevated serum SAP may be correlated with GDM, whereas peripheral PRG4 showed no obvious association with gestational hyperglycemia in this cohort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.